98%
921
2 minutes
20
Objective: In this study, we aimed to investigate retinal changes in a large cohort of amyotrophic lateral sclerosis (ALS) patients and healthy controls (HCs) to further elucidate their relationship with ALS.
Methods: This was a cross-sectional observational study. We evaluated retinal layer thickness in 134 ALS patients and 66 HCs using optical coherence tomography (OCT). Particularly, we focused on the macular region and peripapillary retinal nerve fiber layer (p-RNFL).
Results: The examination of retinal layers in ALS patients revealed a significant change in the inner nuclear layer (INL), with a pattern of initial thickening followed by thinning, which correlated with disease stages, most notably in the inner nasal quadrant. Moreover, the p-RNFL in the temporal quadrant was thinner in ALS patients compared to HCs. In addition, ALS patients who developed bulbar symptoms exhibited marginally thinner p-RNFL in the temporal quadrant compared to those without bulbar symptoms. Interestingly, a thinner p-RNFL in the temporal quadrant did not correlate with faster disease progression.
Conclusion: This study reveals notable changes in the INL and p-RNFL thickness in ALS patients, highlighting the intricate relationship between retinal changes and ALS progression. Despite these retinal alterations, no correlation with disease progression rate was observed. These findings suggest that while OCT shows potential in monitoring ALS, its role in predicting disease course requires further investigation with long-term longitudinal studies and diverse patient cohorts.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jocn.2025.111268 | DOI Listing |
Qual Life Res
September 2025
Centre for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, 600077, India.
Med Klin Intensivmed Notfmed
September 2025
Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
Acute abdomen can represent a serious clinical condition with a variety of different and potentially life-threatening underlying causes. Rapid identification of the underlying etiology through a structured approach and the prompt initiation of adequate diagnostic and treatment measures is highly relevant in order to reduce the patient's mortality risk. This article provides an overview of important differential diagnoses of an acute abdomen and describes recommended diagnostic and therapeutic measures that are relevant in acute and emergency clinical care.
View Article and Find Full Text PDFIn recent years, several biologics have been introduced into hospitals and clinics as alternatives to surgery and/or topical/oral cortisone therapy in patients with severe refractory chronic rhinosinusitis with polyps (CRSwNP). Advances in understanding the pathophysiology of CRSwNP in relation to the predominant type 2 endotype have also paved the way for understanding possible overlaps with hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA). In this article, we present the biologic treatment options currently approved in Germany for the treatment of severe CRSwNP - dupilumab, omalizumab and mepolizumab - together with guidance on practical management including side effects for the indication of CRSwNP.
View Article and Find Full Text PDFActa Neurol Belg
September 2025
Neuroscience Research Australia, University of New South Wales, Sydney, Australia.
Objectives: Patients diagnosed with amyotrophic lateral sclerosis (ALS) typically describe symptoms of fatigue. Despite this frequency, the underlying mechanisms of fatigue are poorly understood, and are likely multifactorial. To help clarify mechanisms, the present systematic review was undertaken to determine the risk factors related to fatigue in ALS.
View Article and Find Full Text PDFImmunotherapy
September 2025
Department of Dermatology and Allergology, University Hospital, LMU Munich, Munich, Germany.
Currently, the first-line treatment of non-metastatic Merkel cell carcinoma (MCC) is complete resection. In case of unresectable or metastatic MCC, immune checkpoint inhibitor (ICI) therapy with avelumab (or in the US also pembrolizumab or retifanlimab) is indicated. We report on a patient with a primary, non-metastatic MCC on the left eyelid and amyotrophic lateral sclerosis (ALS).
View Article and Find Full Text PDF